Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
Former official David Mansdoerfer argues that bureaucratic delays at the FDA threaten American leadership in the growing regenerative medicine sector and give international competitors like China a strategic advantage.
<iframe src="https://statesidedaily.com/embed/cluster/63dbc13db2ad0740b477cf20023d22fc574e362d" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="To outcompete China, unhandcuff America’s biotech innovators"></iframe>
